You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

Authors

  • Wei Wei Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Xiaohua Ban State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China PubMed articlesGoogle scholar articles
  • Fan Yang Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Jibin Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China PubMed articlesGoogle scholar articles
  • Xiaqin Cheng Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Rong Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China PubMed articlesGoogle scholar articles
  • Xin Huang Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Yongwen Huang Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Qiaqia Li Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Ya Qiu Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Min Zheng Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles
  • Xiaofeng Zhu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China PubMed articlesGoogle scholar articles
  • Jundong Li Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China PubMed articlesGoogle scholar articles

Citation

Wei W, Ban X, Yang F, et al
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Journal for ImmunoTherapy of Cancer 2022;10:e004338. doi: 10.1136/jitc-2021-004338
Online issue publication 
May 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.